Due to EGFR gene amplification, protein overexpression, mutations or in-frame deletions, EGFR signalling is frequently altered in a number of human malignancies, including glioblastoma, brain, lung, breast and ovarian cancers (220, 221). This evidence concerns the gene EGFR and ovarian carcinoma.